Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The SURMOUNT-5 data showing 47% greater weight loss with tirzepatide suggests that many partial semaglutide responders would cross the threshold into meaningful weight loss with the stronger medication
Selkoe, D
Lillys triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. PR Newswire, May 21, 2026
Estimates suggest that if Medicare were to cover Ozempic for weight loss, it could cost the program $14 billion to $27 billion per year, or about 3% of Medicares 2022 spending
US$ 20.68
US$ 28.06
US$ 21.50
US$ 25.93
US$ 22.04
US$ 29.00
US$ 21.88
US$ 21.62
US$ 25.60
US$ 25.52
US$ 22.44
US$ 27.49
US$ 23.82
